Johnson & Johnson is seeking a declaratory judgement from the DC federal court stating the Health Resources and Services Administration is not the only entity with the legal authority to implement a rebate model in the 340B outpatient drug discount program and that a manufacturer can implement one without the agency’s authorization.
J&J Opens New 340B Litigation Front With Lawsuit Against HRSA Over Rebate Model
Company’s move against the US agency tasked with overseeing the 340B drug discount program is the latest in a series of manufacturer attempts to rein in ballooning 340B price concessions.
More from Pink Sheet
• By
About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department and experts questioned whether the cuts could be implemented without harming FDA’s core mission.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.
• By
A German ordinance implementing the EU Health Technology Assessment Regulation offers little clarity on how far joint clinical assessment reports should be considered by national authorities.
More from Market Access
• By
Democrats opposed the nomination because they believe Mehmet Oz will not defend Medicaid from spending cuts. His pledge to continue lowering drug costs in Medicare and Medicaid did not offset the concerns.
• By
An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.
• By
The European Medicines Agency is this week set to issue an opinion on whether pan-EU marketing should be granted to Lilly’s Alzheimer’s disease drug donanemab.